¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
 ÀϹݿ¬Á¦ ¹ßÇ¥ ¾È³»

  1. ¹ßÇ¥½Ã°£ ¹× ¹ßÇ¥Àå¼Ò : Çмú´ëȸ ȨÆäÀÌÁö ¡®¹ßÇ¥ÀÚ ¾È³»¡¯¿¡¼­ È®ÀÎ
  2. ¹ßÇ¥½½¶óÀ̵å Á¦Ãâ : 2016³â 9¿ù 19ÀÏ(¿ù)±îÁö office@ksog.org·Î Á¦Ãâ(PPTÆÄÀÏ)
    ¹ßÇ¥½½¶óÀ̵å´Â »çÀü¿¡ ¹Ýµå½Ã Á¦ÃâÇÏ¿©¾ß Çϸç, ¹ßÇ¥ ´çÀÏ ¼öÁ¤µÈ ÆÄÀÏ·Î ±³Ã¼°¡´ÉÇÔ
    (¹ßÇ¥½½¶óÀÌµå ¹ÌÁ¦Ãâ½Ã ¹ßÇ¥Æ÷±â·Î °£ÁÖÇÔ)
  3. ¹ßÇ¥°ü·Ã À¯ÀÇ»çÇ×
    - ½½¶óÀ̵å´Â 15¸Å À̳», 1Àå´ç 10ÁÙ À̳»·Î Á¦ÀÛÀ» ±ÇÀåÇÔ
    - ÁöÁ¤µÈ ¹ßÇ¥½Ã°£(7ºÐ ¹ßÇ¥, 3ºÐ ÁúÀÇÀÀ´ä ÃÑ 10ºÐ)À» ÁؼöÇÏ¿©¾ß ÇÔ
    - ¹ßÇ¥´çÀÏ 4Ãþ Preview Room¿¡¼­ ÃÖÁ¾ ¹ßÇ¥ÆÄÀÏÀ» È®ÀÎÇϰųª ¼öÁ¤ÆÄÀÏÀ» Á¦Ãâ°¡´É
    (»çÀü Á¦ÃâÀÚ·á¿¡¼­ º¯°æÀÌ ¾ø´õ¶óµµ È®ÀÎÇÏ¿©¾ß Çϸç, ƯÈ÷ µ¿¿µ»óÀ» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â È®ÀÎÇʼö)
¸ðüžÆÀÇÇР/   ºÎÀÎÁ¾¾çÇР /   »ý½Ä³»ºÐºñÇР /   ÀϹݺÎÀΰúÇÐ
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2016³â 9¿ù 23ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO01-GO05 (08:20~09:10) ÁÂÀå : ±è¿ë¹ü(¼­¿ïÀÇ´ë)
GO0108:20~08:30 ±âÀº¿µ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Immunocytochemistry negativity for human papillomavirus L1 capsid protein as a biomarker in atypical squamous cell of undetermined significance or low grade squamous intraepthelial lesion
GO0208:30~08:40 È«¿µÈñ
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Impact of Adjuvant Hysterectomy on Prognosis in Patients with Locally Advanced Cervical Cancer Treated with Definitive Chemoradiation: A Meta-Analysis
GO0308:40~08:50 °­¼º¿ì
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: a propensity score matching study
GO0408:50~09:00 ÀÌÀοÁ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Uniformed Indocynine Green injection protocol; the effective factor of increasing optimal sentinel lymph node mapping rate in cervical and endometrial cancers
GO0509:00~09:10 ÀÌÁöÇý
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer
GO06-GO10 (09:10~10:00) ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë)
GO0609:10~09:20 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Germline Mutations in Patients with Epithelial Ovarian Cancer using Gene-Panel Sequencing: Beyond BRCA 1/2
GO0709:20~09:30 À̽ÅÈ­
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Potential urinary biomarker panel to predict malignancy in women with pelvic masses
GO0809:30~09:40 ±Ç¿ëÀÏ
À¯·ÎÁø»êºÎÀΰú
Glycan Markers for Ovarian Cancer with High Sensitivity and High Specificity
GO0909:40~09:50 ÀÌÁ¤¿ø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-cancer Effect of Ulipristal Acetate in Uterine Leiomyosarcoma
GO1009:50~10:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Development of a female animal model for anatomical and functional assessment of the pelvic autonomic nerves in women
GO11-GO15 (10:30~11:20) ÁÂÀå : Çã¼ö¿µ(°¡Å縯ÀÇ´ë)
GO1110:30~10:40 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long non-coding RNA HOXA11 antisense promotes tumor progression and predicts patient prognosis in serous ovarian cancer
GO1210:40~10:50 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The Effect of Chemical inhibition of Lysyl-tRNA Synthase-Laminin Receptor in Ovarian Cancer
GO1310:50~11:00 À±Á¤¼ö
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
The long non-coding RNAs in the epithelial recurrent ovarian cancer
GO1411:00~11:10 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Steroid Receptor Activator modulates proliferation and invasion in the human cervical cancer
GO1511:10~11:20 ¼­µ¿¼ö
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Selective cytotoxic effect of non-thermal micro-DBD plasma in uterine cervical cancer cells
GO16-GO20 (11:20~12:10) ÁÂÀå : ÀÌÀ±¼ø(°æºÏÀÇ´ë)
GO1611:20~11:30 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long Term Survival Analysis of Carboplatin or Cisplatin Based Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
GO1711:30~11:40 À±¹ÎÁ¤
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Dose-dense paclitaxel and carboplatin for ovarian carcinoma among Korean population: single institution experience
GO1811:40~11:50 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Survival impact of low anterior resection in the patients with epithelial ovarian cancer grossly confined to pelvic cavity: A multicenter retrospective study
GO1911:50~12:00 °ûÀ翵
¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú
Adjuvant treatment strategy of pathological down-staged patients after radical surgery of locally advanced cervical cancer with neoadjuvant chemotherapy
GO2012:00~12:10 ¿ÀÁøÁÖ
´ë±¸°¡Å縯´ëÇб³º´¿ø »êºÎÀΰú
The cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance
GO21-GO24 (12:10~12:50) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO2112:10~12:20 ±Ç¹ÎÁ¤
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Rapid genetic screening experience among endometrial cancer about Lynch syndrome by surgeon
GO2212:20~12:30 À¯Áö±Ù
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Prevalence and outcome of BRCA mutation in Korean epithelial ovarian cancer women
GO2312:30~12:40 ÀÓ¿µ¹Ì
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Hypermethylation of the Single-minded homolog 1 (SIM1) as a novel biomarker for cervical cancer screening
GO2412:40~12:50 ÀåűÔ
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
Natural course of HPV positive women in Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion and association of HPV genotype : HPV cohort study
GO25-GO27 (14:00~14:30) ÁÂÀå : ¹®Çý¼º(ÀÌÈ­ÀÇ´ë)
GO2514:00~14:10 ±è¼ö¿µ
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Investigation of physician awareness regarding treatment options for cervical intraepithelial neoplasia 1 by using a survey questionnaire
GO2614:10~14:20 À̹æÇö
ÇѸ²ÀÇ´ë °­µ¿¼º½Éº´¿ø »êºÎÀΰú
Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
GO2714:20~14:30 Á¤¿µ½Å
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
A sufficient number of relevant ethnic controls are needed for accurate assessment according to the ACMG standards and guidelines
GO28-GO30 (14:30~15:00) ÁÂÀå : ±èÈ«¹è(ÇѸ²ÀÇ´ë)
GO2814:30~14:40 ÃÖÀºÁö
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
One institute experience of Robotic Single-Site Surgery, 300 Cases
GO2914:40~14:50 ¹ÚÁöÀº
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Robotic infrarenal paraaortic lymphadenectomy with single-positioning approach using da Vinci Xi system: Initial experiences and comparison with dual-positioning approach using da Vinci S system
GO3014:50~15:00 ÃÖÂ÷Çö
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Usefulness of hemostatic agents for minimizing ovarian damage during laparoscopic cystectomy for endometriosis